Abstract
Two cases of advanced and metastatic breast cancers were treated by docetaxel (TXT) in combination with intra-arterial infusion of adriamycin (ADM). Patients received 60 mg/body TXT i.v. and 30 mg/body ADM ia (AT therapy) bi-weekly. Clinical responses were observed in these two patients and the durations of responses were over 20 weeks. Critical toxicities of grade 2 leukopenia and alopecia were observed but grade 4 severe toxicities were not. Thus AT therapy can be easily and safely performed with outpatients. This therapy can improve the response rate and time to progression; therefore phase I or phase I/II clinical trials of AT therapy in Japan are recommended.
MeSH terms
-
Adult
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents, Phytogenic / administration & dosage*
-
Antineoplastic Agents, Phytogenic / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Breast Neoplasms / drug therapy*
-
Docetaxel
-
Doxorubicin / administration & dosage*
-
Female
-
Humans
-
Infusions, Intra-Arterial
-
Infusions, Intravenous
-
Middle Aged
-
Neoplasm Recurrence, Local
-
Paclitaxel / administration & dosage*
-
Paclitaxel / adverse effects
-
Paclitaxel / analogs & derivatives*
-
Taxoids*
Substances
-
Antineoplastic Agents
-
Antineoplastic Agents, Phytogenic
-
Taxoids
-
Docetaxel
-
Doxorubicin
-
Paclitaxel